T Cell News and Research

Latest T Cell News and Research

Study identifies promising therapy to overcome limitation in brain's ability to recover function after stroke

Stroke is the leading cause of adult disability, due to the brain's limited capacity for recovery. Physical rehabilitation is the only current treatment following a stroke, and there are no medications available to help promote neurological recovery.

4 Nov 2010

Afinitor tablets decrease size of SEGA associated with tuberous sclerosis

The New England Journal of Medicine (NEJM) today published a study that found patients taking Afinitor (everolimus) tablets experienced a decrease in the size of their subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS).

4 Nov 2010

Georgia Tech hosts symposium to discuss sickle cell disease

Georgia Tech will host the Sickle Cell Disease Symposium bringing together researchers, policy experts and community advocates to discuss the latest research and strategies for future success in combating this complex and debilitating blood disorder. The symposium begins at Georgia Tech's Institute for Bioengineering and Bioscience on November 4 and concludes the evening of November 5.

4 Nov 2010

New antibody with SGN-35 drug produces remission in Hodgkin lymphoma

An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38 percent of patients with relapsed or therapy-resistant Hodgkin lymphoma enrolled in a phase I clinical trial, investigators report in the Nov. 4 issue of the New England Journal of Medicine.

4 Nov 2010

Study links positive well-being to higher telomerase activity

Positive psychological changes that occur during meditation training are associated with greater telomerase activity, according to researchers at the University of California, Davis, and the University of California, San Francisco. The study is the first to link positive well-being to higher telomerase, an enzyme important for the long-term health of cells in the body.

4 Nov 2010

Aduro receives $442,000 grant under QTDP program to support Listeria-based immunotherapy platform

Aduro BioTech announced today that it has been awarded two cash grants totaling approximately $442,000 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

4 Nov 2010

BioCurex files patent for synthetic peptide in RECAF test

BioCurex, Inc. today announced that it has filed a new patent within the Patent Cooperation Treaty, which presently includes 142 countries.

4 Nov 2010

Aeolus receives $489,000 grant under QTDP program for two lead compounds

Aeolus Pharmaceuticals, Inc. today announced that it has been awarded a total of approximately $489,000 under the Qualifying Therapeutic Discovery Grant Program (QDTP) administered by the Internal Revenue Service and the Department of Health and Human Services.

4 Nov 2010

Electrolytic Ozone completes Series A funding

Electrolytic Ozone Inc. (EOI) today announced completion of Series A funding. EOI develops and manufactures ultra-compact, safe and reliable ozone generators that harness the benefits of ozone to improve the safety and quality of the human environment. EOI ozone cells enable innovative sanitization, deodorization and preservation applications of ozone for consumer, food safety, health and medical uses.

4 Nov 2010

New simple blood test may help diagnose Niemann-Pick type C disease

A fatal genetic disorder that frequently takes years to diagnose may soon be detectable with a simple blood test, researchers at Washington University School of Medicine in St. Louis and the National Institutes of Health (NIH) report this week in Simple blood test may diagnose deadly Niemann-Pick type C disease.

4 Nov 2010

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2010, and company highlights.

4 Nov 2010

Bortezomib reduces inflammation and promotes bone healing in arthritis models

A new study by Greek researchers suggests that the biologic drug bortezomib (Velcade), a proteasome inhibitor used to treat multiple myeloma (bone marrow cancer), may represent a promising treatment for rheumatoid arthritis (RA). In this study, bortezomib displayed favorable effects in an animal model of inflammatory arthritis that mimics RA, in reducing disease severity and inflammation, and promoting bone healing. Full findings of this study are published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

3 Nov 2010

ADVENTRX submits NDA for Exelbine to FDA

ADVENTRX Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion), or Exelbine.

3 Nov 2010

Top 10 Medical Innovations for 2011

From pill-sized cameras to radioactive compounds that let doctors "see" inside a patient's brain, Cleveland Clinic's Top 10 Medical Innovations for 2011 showcases new techniques, therapies and approaches to treating a host of diseases.

3 Nov 2010

Fibrocell, Meifu to develop and market autologous fibroblast therapies in Asia

Fibrocell Science, Inc. a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has signed an agreement to establish a joint venture (JV) with Hefei Meifu Bio-Tech Limited Co. for developing and marketing autologous fibroblast therapies in Asia, excluding Japan. The JV will be called Fibrocell Science Asia Co. Ltd.

3 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

Lifestyle changes and natural supplements can control blood sugar levels

The holiday season can make it challenging for people with diabetes to keep their blood sugar levels stable. Diabetes expert, Dr. Isaac Eliaz recommends prevention through a number of lifestyle changes and natural supplements.

3 Nov 2010

New technique could help scientists to predict how living prostate tissues respond to therapy

Scientists at the Johns Hopkins Kimmel Cancer Center, University of Helsinki and Stanford University have developed a technique to keep normal and cancerous prostate tissue removed during surgery alive and functioning normally in the laboratory for up to a week.

3 Nov 2010

New global map shows distribution of sickle cell gene

At a global scale, the sickle cell gene is most commonly found in areas with historically high levels of malaria, adding geographical support to the hypothesis that the gene, whilst potentially deadly, avoids disappearing through natural selection by providing protection against malaria.

3 Nov 2010

Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, announced today that it has established a Scientific Advisory Board to help advance the company's research and clinical studies in type 1 diabetes.

3 Nov 2010